Drugs / AZD1208
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01489722 | Feb 2012 → May 2014 | acute myeloid leukemia | AstraZeneca | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01588548 Comparator | Jul 2012 → Jul 2014 | high grade malignant neoplasm, lymphoma | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01489722 ↗ |
| Modality | Small molecule | — CHEMBL3545423 ↗ |
| Route | Oral | “Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops.” NCT01489722 ↗ |